Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Naymagon

Gastroenterology New York, NY Medical Doctor

NPI 1730349218 CMS profile 169748

5 E 98Th St, New York, NY 10029

Open in the dashboard

General payments

$86,502

1,456 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Naymagon of New York, NY is reported in the CMS Open Payments database as having received $86,502 across 1,456 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $46,645 329
2024 General $25,514 281
2023 General $4,275 270
2022 General $4,340 265
2021 General $2,687 157
2020 General $656 34
2019 General $2,385 120

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Naymagon
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Steven Naymagon were reported at $46,645. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Steven Naymagon Gastroenterology median Middle half National median
2019 $2,385 $417 $126–$1,100 $163
2020 $656 $224 $74–$624 $114
2021 $2,687 $352 $106–$1,054 $132
2022 $4,340 $448 $129–$1,270 $149
2023 $4,275 $533 $150–$1,390 $160
2024 $25,514 $605 $160–$1,606 $164
2025 $46,645 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $63,385 160 payments
  2. AbbVie, Inc. $5,126 301 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $3,312 223 payments
  4. Janssen Biotech, Inc. $3,219 138 payments
  5. Celgene Corporation $2,159 205 payments
  6. QOL Medical, LLC $1,157 39 payments
  7. Pfizer Inc. $1,135 53 payments
  8. Merck Sharp & Dohme Corporation $946 45 payments
  9. Janssen Scientific Affairs, LLC $705 5 payments
  10. Lilly USA, LLC $483 26 payments
  11. Other $4,875 261 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $49,059 14 payments
  2. Food and Beverage $26,856 1,416 payments
  3. Travel and Lodging $10,338 21 payments
  4. Education $249 5 payments
Products named General payments · program years 2019–2025
  1. ENTYVIO $62,912 130 payments
  2. XIFAXAN $2,773 188 payments
  3. RINVOQ $2,292 125 payments
  4. ZEPOSIA $2,141 203 payments
  5. TREMFYA $2,128 56 payments
  6. STELARA $1,935 88 payments
  7. SKYRIZI Immunology $1,244 84 payments
  8. SKYRIZI Immunology $1,227 72 payments
  9. XELJANZ $993 47 payments
  10. LINZESS $930 49 payments
  11. Other $11,724 610 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

836

Median for Gastroenterology: 569

Drug cost

$869,240

Median for Gastroenterology: $104,976

Branded share of claims

42.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 19 $453,443
Remicade Infliximab Brand 14 $112,643
Rinvoq Upadacitinib Brand 12 $73,164
Dificid Fidaxomicin Brand 11 $52,301
Octreotide Acetate Generic 14 $39,844
Linzess Linaclotide Brand 37 $32,019
Zenpep Lipase/Protease/Amylase Brand 11 $28,252
Yusimry(Cf) Pen Adalimumab-Aqvh Brand 11 $19,360
Mesalamine Generic 45 $19,056
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 60 $10,173

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$393,011

Of which drugs: $251,340

Medicare patients

598

Average age 76

Services billed

15,794

360 women, 238 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 51%
Ischemic heart disease 35%
Diabetes 31%
Osteoporosis 28%
Cancer 24%
Atrial fibrillation 21%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 11 11,700 $204,590
Infusion, normal saline solution, 250 cc J7050 Office 14 54 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
$20,787 — 11,700
RINVOQ
$455 12 —
ZEPOSIA
$451 — —
SKYRIZI
$437 — —
STELARA
$300 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

1,456 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record